CELGENE AVILOMICS RESEARCH INC has a total of 29 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2008. It filed its patents most often in Australia, Taiwan and Israel. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are BRISTOL MYERS SQUIBB PHARMA CO, ITEOS THERAPEUTICS and LYCERA CORP.
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Computer technology | |
#5 | Foods and drinks | |
#6 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Organic chemistry methods | |
#6 | Enzymes | |
#7 | Measuring microorganism processes | |
#8 | Bioinformatics | |
#9 | Computational chemistry | |
#10 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Singh Juswinder | 21 |
#2 | Niu Deqiang | 19 |
#3 | Qiao Lixin | 16 |
#4 | Kluge Arthur F | 13 |
#5 | Petter Russell C | 11 |
#6 | Zhu Zhendong | 8 |
#7 | Ghosh Shomir | 8 |
#8 | Petter Russell | 5 |
#9 | Tester Richland Wayne | 5 |
#10 | Lee Kwangho | 4 |
Publication | Filing date | Title |
---|---|---|
AU2016210788A1 | Algorithm for designing irreversible inhibitors | |
AU2015224469A1 | HCV protease inhibitors and uses thereof | |
AU2015224437A1 | HCV protease inhibitors and uses thereof | |
AU2014200319A1 | Algorithm for designing irreversible inhibitors | |
AU2012321091A1 | Methods of treating a Bruton's Tyrosine Kinase disease or disorder | |
TW201124399A | Heteroaryl compounds and uses thereof | |
AU2008340257A1 | HCV protease inhibitors and uses thereof |